Showing 7951-7960 of 9735 results for "".
- Juvéderm Voluma XC Approved for Enhancement of the Chin Regionhttps://practicaldermatology.com/news/juvederm-voluma-xc-approved-for-enhancement-of-the-chin-region/2460426/The FDA has approved a new indication for Juvéderm Voluma XC for the augmentation of the chin region to improve the chin profile in adults over the age of 21. The Juvéderm Collection of Fillers has the broadest portfolio of specifically tailored treatment options, and this latest ap
- Further Evidence of Long-term Use and Cost-effectiveness of Ilumya for Psoriasis Presented at Virtual AADhttps://practicaldermatology.com/news/further-evidence-of-long-term-use-and-cost-effectiveness-of-ilumya-for-psoriasis-presented-at-virtual-aad/2460425/Sun Pharmaceutical Industries Ltd. presented further evidence of the long-term use and cost-effectiveness of tildrakizumab-asmn (Ilumya) in moderate to severe plaque psoriasis at the American Academy of Dermatology (AAD) Virtual Meeting Experience 2020. Long-term analyses of the reSURFA
- ProTransit to Target Photodamage in Trials of New Nanoparticle Technologyhttps://practicaldermatology.com/news/protransit-to-target-photodamage-in-trials-of-new-nanoparticle-technology/2460418/ProTransit Nanotherapy plans to launch human clinical trials this summer with products that could target precursors of skin cancers. The company has developed therapies based nanoparticle technology invented at the University of Nebraska Medical Center to help prevent and potentially improve suns
- Dermata Reports Positive Results for Once-Weekly Topical Application of DMT310 in Acnehttps://practicaldermatology.com/news/dermata-reports-positive-results-for-once-weekly-topical-application-of-dmt310-in-acne/2460417/Dermata Therapeutics' lead clinical candidate, DMT310, performed well in a Phase 2b study of moderate-to-severe acne vulgaris. Once-weekly DMT310 achieved Investigator Global Assessment (IGA) success (2-point change & 0 or 1) in 44.4 percent of patients versus 17.8 percent
- Hoth Therapeutics Obtains Full Licensing Rights for BioLexa Platform, Atopic Dermatitis Treatmenthttps://practicaldermatology.com/news/hoth-therapeutics-obtains-full-licensing-rights-for-biolexa-platform-atopic-dermatitis-treatment/2460397/Hoth Therapeutics, Inc. has obtained exclusive worldwide licensing rights to the BioLexa Platform, a proprietary, patented antimicrobial therapy focused on treating atopic dermatitis. This agreement serves as an extension to the previo
- New Medscape Physician Compensation Report: Derms Earn About $411Khttps://practicaldermatology.com/news/new-2020-medscape-physician-compensation-report-derms-earn-about-411k/2460394/The 2020 Medscape Physician Compensation Report is out, and it shows that dermatologists earn an average of $411K per year, down 2 percent from 2019. Plastic surgeons earn $479K per year on average, up 2 percen
- NRS Roundtable: Greater Focus on Facial Erythema in Rosacea Warrantedhttps://practicaldermatology.com/news/nrs-roundtable-greater-focus-on-facial-erythema-in-rosacea-warrated/2460392/Dermatologists should place greater emphasis on addressing persistent facial erythema in roscaea, according to experts at a recent National Rosacea Society (NRS) roundtable. Drawing from current scientific knowledge as well as clinical experience, the new standard classification of rosa
- Accure Laser Gets CE Mark for Acne Treatmenthttps://practicaldermatology.com/news/accure-laser-gets-ce-mark-for-acne-treatment/2460386/Accure Acne, Inc. now has a European CE mark for its groundbreaking Accure Laser™ system to treat patients with moderate acne vulgaris. The Accure Laser is the first commercially-developed light-based platform in the world to selectively target and injure sebaceous glands. Fo
- COVID-19 By the Numbers: May 5 Editionhttps://practicaldermatology.com/news/covid-19-by-the-numbers-may-5-edition/2460375/Sixteen states have significantly reduced COVID-19 restrictions, while 18 have somewhat reduced restrictions, a new analysis from WalletHub reveals. The easing comes as the US reports nearly 70,000 COVI
- FDA Approves Galderma's Restylane Kysse for Lip Augmentation and Upper Perioral Rhytidshttps://practicaldermatology.com/news/fda-approves-galdermas-restylane-kysse-for-lip-augmentation-and-upper-perioral-rhytids-1/2460374/The FDA has approved Galderma'a Restylane Kysse for lip augmentation and the correction of upper perioral rhytids in adults over the age of 21. Restylane Kysse is the first hyaluronic acid (HA) filler specifically indicated for the lips using XpresHAn Technology globally referred to as the OB